WALTHAM, Mass. (AP) -- Drug developer Repligen said Tuesday that Biogen Idec executive John Cox is joining its board of directors.
Cox has worked for Biogen Idec Inc. since 2003 and has been in charge of its pharmaceutical operations and technology since June 2010.
Repligen also said Earl Henry will retire from its board at the end of the year. He has been a company director since 2007.
Non-employee directors of Repligen Corp. get an annual retainer of $35,000, with additional payments depending on membership in various board committees.